(Q33953263)

30 July 2017

1 reference

title

Potential new treatments for type 2 diabetes (English)

1 reference

30 July 2017

1 reference

C J Bailey

1

1 reference

30 July 2017

publication date

1 July 2000

1 reference

Trends in Pharmacological Sciences

30 July 2017

published in

1 reference

30 July 2017

volume

21

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

259-265

1 reference

Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Long-term complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Lilly Lecture 1993. Glycation and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Recent progress in advanced glycation end products and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Pathophysiology of insulin resistance in human disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Insulin resistance and antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

1 reference

7 January 2021

A risk-benefit assessment of metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Hyperglycemia and microvascular and macrovascular disease in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Long-term effects of modest weight loss in type II diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Cardiovascular risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Glycemic control and cardiovascular disease in type 2 diabetes: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Role of JTT-501, a new insulin sensitiser, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Vanadium compounds biological actions and potential as pharmacological agents

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Protein tyrosine phosphatases: their role in insulin action and potential as drug targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta2 and theta

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Discovery of a Small Molecule Insulin Mimetic with Antidiabetic Activity in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

New non-sulfonylurea insulin secretagogues

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

ATP-sensitive K+ channels and insulin secretion: their role in health and disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Erythromycin improves glycaemic control in patients with Type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Magnesium supplementation in the treatment of diabetes. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Antioxidant defense: vitamins E and C and carotenoids

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Engineering cultured insulin-secreting pancreatic B-cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Prospects for insulin delivery by ex-vivo somatic cell gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901506-6

7 January 2021

Effect of captopril, losartan, and bradykinin on early steps of insulin action

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.2337/DIAB.46.12.1950

Identifiers

DOI

10.1016/S0165-6147(00)01506-6

1 reference

30 July 2017

1 reference